SMi Presents the 3rd Annual Conference: Injectable Drug Delivery 2020

SMi Group 13 - 14 May 2020, London, UK.
SMi Group is pleased to announce the third annual Injectable Drug Delivery conference, which will be held in London. Part of Europe's leading Injectable conference series, Injectable Drug Delivery will assess innovations in drug product formulation and biologics, innovations in device design, quality management and connectivity for enhanced subcutaneous delivery.

With rapid developments in the parenteral space, the injectable drug delivery market is set to reach USD 902.3 billion by 2027, with an increased focus on patient centricity during DDC development and innovations in device development, including new therapeutic applications such as the delivery of siRNA. This year's event will focus on advances in drug product formulation and innovations of device design and development to aid delivery.

Furthermore, the conference will assess the evolving regulatory environment of injectable drug delivery with industry and regulatory representatives presenting updates on current guidelines.

The two-day agenda also offers peer-to-peer networking with Global Product Managers, Device Testing Managers, Senior Device Engineers, Heads of Device Development, Heads of Formulation and Drug Process Development, and many more.

The benefits of attending

This conference offers a chance to learn about innovative injectable drug delivery systems with industrial insights on the following:
  • DELVE into the latest work in complex formulation for subcutaneous delivery
  • BENCHMARK against leading pharma companies working to enhance device design and development
  • UNDERSTAND the regulatory environment of the injectables space from leading regulatory and industry advisors
  • ENGAGE in industry case studies on design controls, human factors and parenteral formulation
  • EXPLORE advances in connectivity and human factors key learnings in two pre-conference workshops

Who should attend

Executives, Directors, VPs, Heads, Principals, Managers, Scientists, Researchers of:
  • Autoinjectors
  • Wearables
  • Device Engineering
  • Human Factors
  • CMC
  • Injectables
  • Sterile Manufacturing
  • Packaging
  • Regulatory Affairs

Featured Speakers

  • Alexander Zuern,Device testing manager, Novartis International AG
  • Andrew Warrington, Project Leader & Patient Advocate, Novartis
  • Benjamin Werner,Scientist, Boehringer Ingelheim Pharma GmbH & Co. KG
  • Bjorg K Hunter, Regulatory Manager, Devices, GSK
  • Blake Green, Senior Manager Regulatory Affairs, Amgen
  • Camille Dagallier, Formulation and Drug Process Development Senior Scientist, Sanofi
  • Christopher Muenzer, Senior Device Technology Manager, Novartis
  • Joel Richard,Head of Technical & Pharmaceutical Operations, MedinCell
  • Mark Palmer, Scientific Leader, Biopharm Device Engineering, GSK
  • Rebecca Moses, Director, Core Human Factors Inc.
  • Rupal Nguyen, Principal Engineer, Allergan
  • StefaniaRagone, Pharmaceutical Assessor, Medicines & Healthcare Products Regulatory Agency (MHRA)
  • Tina Arien, Principal Scientist, Janssen Pharmaceutica
  • Vikas Jaitely, Director, Global Regulatory Affairs Transitional Medicine and Devices, Merck

Early-bird rates

  • Book by 31st January and save £400
  • Book by 28th February and save £300
  • Book by 29th March and save £200

For further information and to register, please visit:
http://www.injectable-drug-delivery.com/wpnwl

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.

Most Popular Now

AstraZeneca to donate 9 million face masks to supp…

AstraZeneca is donating nine million face masks to support healthcare workers around the world as they respond to the COVID-19 (novel coronavirus) global pandemic. AstraZ...

Singapore modelling study estimates impact of phys…

A new modelling study conducted in a simulated Singapore setting has estimated that a combined approach of physical distancing [2] interventions, comprising quarantine (f...

Roche response to COVID-19 pandemic

Roche Group (SIX: RO, ROG; OTCQX: RHHBY), provided an update on the various actions the company is taking to address the COVID-19 pandemic. On March 19, 2020, Roche co...

Amgen and the Amgen Foundation commit up to $12.5 …

Amgen (NASDAQ:AMGN) and the Amgen Foundation announced an initial commitment of up to $12.5 million to support U.S. and global relief efforts to address critical needs in...

Novartis and life sciences companies commit expert…

Novartis and a consortium of life sciences companies announced an important collaboration to accelerate the development, manufacture and delivery of vaccines, diagnostics...

CAR macrophages go beyond T cells to fight solid t…

Chimeric antigen receptor (CAR) T cell therapy has been a game-changer for blood cancers but has faced challenges in targeting solid tumors. Now researchers from the Pere...

Vivli to launch a portal for sharing data from COV…

In a visible sign of data sharing leadership, Vivli, the Center for Clinical Research Data has committed to serving the open science community through the launch of a COV...

Roche initiates Phase III clinical trial of Actemr…

Roche (SIX: RO, ROG; OTCQX: RHHBY) is working with the Food & Drug Administration (FDA) to initiate a randomised, double-blind, placebo-controlled Phase III clinical tria...

Novartis commits to donate up to 130 million doses…

Novartis announced its commitment to donate up to 130 million doses of generic hydroxychloroquine to support the global COVID-19 pandemic response. Hydroxychloroquine and...

Understanding how COVID-19 affects children vital …

Though COVID-19 so far appears to be largely sparing children, researchers are cautioning that it is critical to understand how the virus affects kids to model the pandem...

Nafamostat is expected to prevent the transmission…

Nafamostat mesylate (brand name: Fusan), which is the drug used to treat acute pancreatitis, may effectively block the requisite viral entry process the new coronavirus (...

Experimental AI tool predicts which COVID-19 patie…

An artificial intelligence tool accurately predicted which patients newly infected with the COVID-19 virus would go on to develop severe respiratory disease, a new study ...